
    
      The purpose of this study is to evaluate the safety, efficacy, and tolerability of a 0.5% BID
      concentration of RVT-501 in pediatric patients 2-17 years of age with mild to moderate atopic
      dermatitis. The pharmacokinetics of RVT-501 will also be evaluated in patients 2-11 years of
      age.
    
  